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osting by EAbstract Diabetic retinopathy (DR) is a major cause of preventable blindness in the developed
countries. Despite the advances in understanding and management of DR, it remains a challenging
condition to manage. The standard of care for patients with DR include strict metabolic control of
hyperglycemia, blood pressure control, normalization of serum lipids, prompt retinal laser photo-
coagulation and vitrectomy. For patients who respond poorly and who progressively lose vision in
spite of the standard of care, intravitreal administration of steroids or/and anti-vascular endothelial
growth factor (anti-VEGF) drugs appear to be a promising second-line of therapy. This review dis-
cusses the current concepts and the role of these novel therapeutic approaches in the management of
DR.
ª 2010 King Saud University. All rights reserved.Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
2. Causes of visual loss in DR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
3. Standard of care in DR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
4. Intravitreal drugs for managing DR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
5. Intravitreal steroid injections (Silva et al., 2009) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146thalmology Section, P.O. Box
a, Qatar. Tel.: +974 6514206.
(A. Pai).
ity. All rights reserved. Peer-
d University.
lsevier
1144 A. Pai et al.5.1. Intravitreal steroids for DME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
5.2. Intravitreal steroids for PDR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
6. Anti-VEGF therapy in DR (Neelakshi et al., 2009; Jardeleza and Miller, 2009) . . . . . . . . . . . . . . . . . . . . . . . . . . . 1466.1. Bevacizumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6.2. Ranibizumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6.3. Pegaptanib . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6.4. VEGF Trap-eye . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1477. Combination therapy with intravitreal steroids and anti-VEGF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
8. Combination therapy with laser and intravitreal drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
9. Enzymatic vitreolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
0. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1481. Introduction
There is an epidemic of diabetes mellitus (DM) worldwide
(Scanlon, 2009). Prevalence of diabetic retinopathy (DR) is also
rising accordingly.DR is themajor threat to sight in theworking
age population in the developed world (Zimmet et al., 2001).
Furthermore, DR is increasing as a major cause of blindness
in other parts of world including the eastern Mediterranean
and middle eastern region representing an enormous public
health problem (Scanlon, 2009; Zimmet et al., 2001).
The extent of visual impairment in diabetic patients with
DR can undeniably be decreased with systemic and ocular ther-
apeutic intervention as shown by many clinical trials. For last
few decades, retinal laser photocoagulation has led a revolution
in the management of diabetic retinopathy. Just as dramatic as
laser photocoagulation, advances in instrumentation and vit-
reo-retinal surgical techniques have also been able to salvage vi-
sion in many patients with advanced stages of DR.
Since the DR is a complex entity with multi-factorial etiol-
ogy it needs multipronged approach to treatment. Though the
laser photocoagulation has remained as the mainstay of treat-
ment for patients with DR, there is a distinct sub-group of eyes
with DR which do not respond adequately to laser photocoag-
ulation. This limitation has promoted interest to search for
alternative treatment modalities. Several therapeutic modali-
ties are under investigation presently. This article will address
the current concepts in the management of DR with intravitre-
al administration of drugs.Figure 1 Classiﬁcation of diabetic retinopathy.2. Causes of visual loss in DR
Though the diabetic retinopathy progresses through various
stages, as shown in Fig. 1, the treatment of DR in a patient de-
pends on the cause/s of visual loss. The two main causes of vi-
sual loss/impairment in patients with diabetic retinopathy are:
proliferative diabetic retinopathy (PDR) and diabetic macular
edema (DME).
Retinal neovascularization, a hallmark of proliferative dia-
betic retinopathy (PDR), is considered a major risk factor for
severe vision loss in patients with DM (Abdulla and Fazwi,
2009). PDR can be further categorized as early, high-risk, or
advanced, depending on the degree and severity of retinal
new vessels, presence of vitreous or pre-retinal hemorrhage
and retinal detachment.The diabetic macular edema (DME) in the most common
cause of moderate visual loss in patients with DM (Klein
et al., 1984; Moss et al., 1988). DME may be associated with
any of the stages of retinopathy. DME is deﬁned as retinal
thickening or presence of hard exudates within one disc diam-
eter of the centre of the macula (The Early Treatment of Dia-
betic Retinopathy Study Research Group, 1985; Klein et al.,
1991, 1995; Neelakshi et al., 2009). The Early Treatment of
Diabetic Retinopathy Study (ETDRS) further classiﬁed
DME as either clinically signiﬁcant macular edema (CSME)
or non-clinically signiﬁcant, depending on its location and
the presence of any associated exudates (Neelakshi et al.,
2009; Wilkinson et al., 2003). DME becomes CSME if one
or more of the following three conditions are present: (a) reti-
nal thickening at or within 500 lm of the centre of the macula,
(b) hard exudates at or within 500 lm of the centre of the mac-
ula if associated with thickening of the adjacent retina, (c) a
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in size part of which is within one disc diameter of the centre of
macula (The Early Treatment of Diabetic Retinopathy Study
Research Group, 1985).
The CSME is further classiﬁed into focal or diffuse type
depending on the pattern of the dye leakage on ﬂuorescein angi-
ography (FA) (Neelakshi et al., 2009). In focal CSME, focal
leakage tends to occur from microaneurisms often with extra-
vascular lipoproteins in circinate pattern around them; and well
deﬁned areas of ﬂuorescein leakage from the microaneurisms
are seen on the FA. These microaneurisms are thought to cause
the retinal thickening. In contrast, the diffuse type of CSME re-
sults from a generalized breakdown of the blood–retinal barrier
resulting into profuse leakage from the entire capillary bed in
the posterior pole. The diffuse CSME is characterized by gen-
eralized intraretinal leakage from the retinal capillary bed
and/or from intraretinal microvascular abnormalities (IRMAs)
and/or from arterioles and venules (in severe cases), without
any discrete areas of leakage from the microaneurisms. Hence
diffuse CSME is more challenging to manage as compared to
the focal type (Neelakshi et al., 2009).Table 1 Intravitreal drugs for DR.
Steroids
Triamcinolone acetonide
Triamcinolone acetonide implant (I-vation)










Microplasmin3. Standard of care in DR
Several large, randomized, controlled clinical trials have pro-
vided the scientiﬁc basis for taking care of vision in the diabetic
patients with DR (The Early Treatment of Diabetic Retinopa-
thy Study Research Group, 1985; The Diabetes Control and
Complications Trial Research Group, 1993; UK Prospective
Diabetes Study (UKPDS) Group, 1998; The Diabetic Retinop-
athy Study Research Group, 1976, 1981, 1987; Early Treat-
ment Diabetic Retinopathy Study Research Group, 1991).
The guidelines set forth by these landmark studies have re-
duced the incidence of visual impairment/loss by helping the
clinician in determining when and how to treat the DR (The
Early Treatment of Diabetic Retinopathy Study Research
Group, 1985; The Diabetes Control and Complications Trial
Research Group, 1993; UK Prospective Diabetes Study
(UKPDS) Group, 1998; The Diabetic Retinopathy Study Re-
search Group, 1976, 1981, 1987; Early Treatment Diabetic
Retinopathy Study Research Group, 1991).
The ﬁrst step in managing DR is to control the underlying
DM because prolonged hyperglycemia is a major risk factor
for the development and progression of DR. Intensive meta-
bolic control, as reﬂected by the HbA1c level, not only reduces
the mean risk of developing retinopathy but also lowers the
risk of progression (The Diabetes Control and Complications
Trial Research Group, 1993; UK Prospective Diabetes Study
(UKPDS) Group, 1998). The available data also suggests that
proper management of hypertension can reduce diabetes-
induced retinal complications (Funatsu and Yamashita, 2003;
Matthews et al., 2004; Sheth et al., 2006). Hyperlipidemia has
been linked to the presence of retinal hard exudates in patients
with retinopathy and evidence suggests that lipid-lowering ther-
apy may reduce hard exudates and microaneurisms (Sheth
et al., 2006; Lyons et al., 2004; Miljanovic et al., 2004; Chew
et al., 1996; Klein et al., 1991). It is important to appreciate that
these treatments not only delay the onset of DR but also slow
the progression of retinal lesions to more severe forms.
Over last 2–3 decades, laser photocoagulation has remained
as the mainstay and the standard of care for managing patientswith sight threatening DR: both PDR and DME (The Early
Treatment of Diabetic Retinopathy Study Research Group,
1985; Neelakshi et al., 2009; The Diabetic Retinopathy Study
Research Group, 1976, 1981, 1987). Panretinal photocoagula-
tion (PRP) with lasers is the standard practice of managing
PDR (The Diabetic Retinopathy Study Research Group,
1976, 1981, 1987). Laser photocoagulation reduces the oxygen
demand of the outer layers of the retina and helps divert
adequate oxygen and nutrients to the inner retinal layers,
thus favorably altering the haemodynamics and introducing
more choroidal oxygen to the ischemic inner retina, with a
resultant reduction in hypoxia-mediated secretion of vascular
endothelial growth factor (VEGF) and regression of neovascu-
larization. In patients with DME too, the retinal laser photo-
coagulation in the form of focal laser for focal CSME or
grid laser for diffuse CSME, as deﬁned by the ETDRS,
remains the standard of care (The Early Treatment of Diabetic
Retinopathy Study Research Group, 1985; Neelakshi et al.,
2009).
4. Intravitreal drugs for managing DR
Some patients with PDR and DME continue to lose vision de-
spite the prompt laser treatment. Progression of visual loss
continues to occur in 5% of patients in patients with PDR in
spite of PRP (Aiello, 2005). In some patients of DME espe-
cially of diffuse CSME, the standard treatment with grid laser
is somewhat less effective and more variable in outcome
(Neelakshi et al., 2009). Thus, in day-to-day practice one com-
monly encounters some cases that are not/less responsive to
the conventional laser therapy.
Many theories have been proposed to explain the clinico-
pathological ﬁndings in PDR and DME, including biochemi-
cal, hemodynamic, endocrine, growth factors and inﬂamma-
tory theories. Hence, it may be inadequate to treat PDR and
DME with laser alone. These newer insights into the pathogen-
esis of DR have improved our understanding of the disease
and helped devise new treatment options with alternative or
adjunctive pharmacologic therapies for those cases that are
not responsive to thermal laser therapy.
Different drugs and drug delivery systems are being tried in
patients with DR. Some of them include: peribulbar steroid
injections, intravitreal steroid injections, injection of sus-
tained-release steroid intravitreal implants and intravitreal
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used as ‘‘off-label’’ therapy. But some of them appear to be
having more convincing roles in the management of DR espe-
cially in the patients with DME who are refractory to laser
photocoagulation. All of these drugs (as shown in Table 1)
are in different levels of clinical trials. Currently none of these
medications have received approval from the Federal Drug
Agency (FDA, USA) to treat DR.
Given the roles of up-regulated inﬂammatory mediators
and vascular endothelial growth factors (VEGF) in the patho-
genesis of DR, intravitreal steroids and intravitreal anti-VEGF
therapy are commonly being used as second-line therapy for
patients with DR which are not responsive to laser therapy.
Hence, we will discuss the roles of intravitreal steroids and
intravitreal anti-VEGF therapy in greater detail.5. Intravitreal steroid injections (Silva et al., 2009)
The concept that DR is a low-grade chronic inﬂammatory
condition is gaining acceptance. Corticosteroids are potent
anti-inﬂammatory agents. In addition, they have been shown
to inhibit the expression of VEGF, effectively reduce vascular
permeability, prevent blood–retinal barrier breakdown and in-
hibit certain matrix metalloproteinases. This broad biologic
activity and multiple pharmacologic effects of corticosteroids
support the rationale behind its use for treatment for DME
and PDR.
Among the corticosteroids being used in managing the DR,
triamcinolone acetonide (TA) is more popular. TA can be
administered by several routes, including intravitreal depot
injection, periocular injection, posterior subtenon injection
and intravitreal implant.
5.1. Intravitreal steroids for DME
Intravitreal administration of depot preparation of TA is an
emerging therapy for persistent DME. Though it has been
used in the dosages of 1–8 mg; the commonly used dosage is
4 mg. The DME often improves after injection along with
the visual acuity. Intravitreal TA has demonstrated short-term
efﬁcacy for DME in multiple clinical trials. After depot injec-
tion, corticosteroid action peaks at 1 week, with residual activ-
ity persisting for 3–6 months. The two most common
complications of intravitreal TA are cataract formation and
raised intraocular pressure. The other less common complica-
tions reported with intravitreal TA injections are: endophthal-
mitis and rhegmatogenous retinal detachment. Peribulbar,
rather than intravitreal, triamcinolone may reduce the risk of
these adverse events. However, peribulbar triamcinolone ap-
pears to be less effective for DME than its intravitreal injection
in multiple clinical trials.
Diabetic Retinopathy Clinical Research network
(DRCR.net) which conducted a randomized clinical multicen-
tric trial comparing intravitreal TA with macular laser treat-
ment reported that the visual acuity seemed to improve
faster in the 4-mg TA group than in the laser group (Diabetic
Retinopathy Clinical Research Network, 2008). But, the mean
visual acuity and the reduction in the central retinal thickness,
as measured by optical coherence tomography (OCT), at
2 years after starting the treatment were better in the laser
group compared to the TA group (Diabetic Retinopathy Clin-ical Research Network, 2008). Cataract formation was more in
4-mg TA group as compared to 1-mg TA group and laser
group. This study indicated that focal/grid laser is a better
treatment than TA in eyes with DME involving fovea with vi-
sual acuity between 20/40 and 20/320 (Diabetic Retinopathy
Clinical Research Network, 2008).
Intravitreal TA injection is a promising therapy for DME
unresponsive to laser therapy. But, some patients require re-
injections as the therapeutic effect of TA diminishes after 3–
6 months. Repeated injections carry risk and are inconvenient
to patients. To reduce the need for repeated intravitreal injec-
tions, a non-biodegradable intravitreal implant, Retisert, has
been developed for the extended-release of ﬂucinolone aceto-
nide within the posterior segment; and it is in phase 3 clinical
trials. The other sustained-release steroid implants being eval-
uated for DME are: dexamethasone implants (Posidurex,
Allergan, CA, USA) and TA implant (I-vation, Surmodics)
both of which are in various levels of clinical trials.
5.2. Intravitreal steroids for PDR
PRP remains the current standard of care in the treatment of
PDR. But, when PDR occurs concurrently with clinically sig-
niﬁcant DME, management becomes more complex. As PRP
has been reported to cause or worsen CSME, some prospective
trials have been conducted to evaluate the role of combination
of intravitreal triamcinolone with PRP in the management of
PDR coexisting with CSME. Several small, clinical trials dem-
onstrated that the combination of laser photocoagulation
(PRP laser and macular laser) with intravitreal TA was associ-
ated with improved visual acuity and decreased central macu-
lar thickness when compared with laser photocoagulation
alone for the treatment of PDR and macular edema (Kang
et al., 2006; Lam et al., 2007; Maia et al., 2009). Further
studies are required to elucidate the role, long-term efﬁcacy
and safety of intravitreal injection of steroids in patients with
PDR.6. Anti-VEGF therapy in DR (Neelakshi et al., 2009; Jardeleza
and Miller, 2009)
In the patho-physiologic cascade which leads to the DR,
chronic hyperglycemia leads to ischemia which results in
over-expression of a number of growth factors, including vas-
cular endothelial growth factors (VEGF). Though blockade of
all involved growth factors will likely be necessary to com-
pletely suppress the detrimental effects of ischemia, even iso-
lated blockade of VEGF may have beneﬁcial effects in DR.
VEGF is an endothelial-cell-speciﬁc angiogenic factor and
it appears to play a major role in pathologic as opposed to
physiologic, ocular neovascularization leading to PDR. VEGF
is also a vasopermeable factor which increases vascular perme-
ability by relaxing endothelial cell junctions and this mecha-
nism is known to contribute to the development of DME.
Inhibition of VEGF blocks these effects to some extent in
DR, as demonstrated in several recent clinical trials and case
series involving the anti-VEGF molecules. Currently, the
anti-VEGF molecules which are commonly being studied in
the management of DR are: pegaptanib (Macugen), rani-
bizumab (Lucentis), bevacizumab (Avastin) and VEGF
Trap-eye. Of the available VEGF antagonists, bevacizumab
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cause it is less expensive.
6.1. Bevacizumab
Bevacizumab is a full-length, recombinant, humanized anti-
body active against all isoforms of VEGF-A. Several studies
reported the use of the off-label intravitreal injection of bev-
acizumab to treat DME and PDR. The commonly used typical
dose is 1.25 mg, although doses as low as 6.2 lg and as high as
2.5 mg have been used.
Many studies have demonstrated beneﬁcial effects follow-
ing intravitreal bevacizumab in patients with DME. Increased
visual acuity with decrease in central retinal thickness with a
single injection of bevacizumab lasts for 4–6 weeks. Hence re-
peated injections may be required for a prolonged effect. How-
ever, bevacizumab’s safety for intravitreal use for DR has not
been tested in large, randomized studies.
Intravitreal bevacizumab injection is an effective adjunct to
conventional PRP in the treatment of PDR. Administering
bevacizumab in conjunction with PRP for PDR results in
greater and rapid regression of new vessels compared with
PRP alone (Tonello et al., 2008; Mirshahi et al., 2008; Jorge
et al., 2006). Bevacizumab also plays a role in the treatment
of actively leaking new vessels refractory to adequately done
laser in PDR. Some authors have studied the use of intravitreal
bevacizumab in cases with dense vitreous hemorrhage that pre-
cludes the completion of PRP (Spaide and Fisher, 2006; Mora-
dian et al., 2008). This approach was suggested as an option
for patients who refuse surgery or are unable to undergo sur-
gery due to their general condition (Abdulla and Fazwi,
2009). Bevacizumab has also shown to prevent or lessen PRP
associated macular edema. Moreover, bevacizumab can be
very helpful in PDR complicated by neovascular glaucoma
(Abdulla and Fazwi, 2009).
Intravitreal bevacizumab injection a few days before the
planned surgery facilitates surgical removal of ﬁbrovascular
membranes, reduces intra-operative bleeding, reduces intra-
operative time, prevents re-bleeding, and helps in accelerating
post-operative vitreous clear-up (Ishikawa et al., 2009; Yeoh
et al., 2008; Chen and Park, 2006; Rizzo et al., 2008). However,
since, tractional retinal detachment may occur or progress
shortly following the intravitreal bevacizumab, the surgery
should be done within few days after its pre-operative injection
in these patients.
Persistent and recurrent vitreous hemorrhage after vitrec-
tomy is a common complication associated with vitrectomy
for diabetic retinopathy with an incidence ranging from 12%
to 63% (Abdulla and Fazwi, 2009; Novak et al., 1984; Yang
et al., 2008). Recurrent vitreous hemorrhage could delay visual
rehabilitation and occasionally requires additional surgical
procedures. It has been seen that the use of intravitreal bev-
acizumab at the end of surgery with or without supplementary
endophotocoagulation reduces the incidence of re-bleeding.
6.2. Ranibizumab
Ranibizumab is a recombinant humanized antibody fragment
that is active against all isoforms of VEGF-A. The commonly
used intravitreal dosage of ranibizumab is 0.5 mg. Its usage is
also off-label in DR in patients with DR. Like bevacizumab,
ranibizumab is also being used for both DME and PDR. Somestudies on intravitreal ranibizumab have demonstrated re-
duced foveal thickness and satisfactory visual outcome in pa-
tients with DME. Currently, READ-2 (Ranibizumab for
Edema of the mAcula in Diabetes), a phase II study is ongoing
in USA, to test the long-term safety and effectiveness of intra-
ocular injections of ranibizumab in patients with DME.
DRCR.net is also conducting randomized clinical trials to elu-
cidate the role of ranibizumab in patients with PDR.
6.3. Pegaptanib
Pegaptanib is an aptamer that binds the VEGF-A 165 isoform.
It differs from the above two anti-VEGF drugs in that instead
of targeting all active VEGF-A isoforms, it prevents only
VEGF-165 and larger isoforms from attaching to the VEGF
receptors. Its intravitreal usage has shown good visual acuity
outcomes, reduced central retinal thickness and reduced need
for additional photocoagulation therapy in patients with
DME. The retrospective analysis of the data of one study on
patients who had concomitant DME and PDR at baseline,
also demonstrated regression of new vessels after pegaptanib
administration (Adamis et al., 2006).
Given the potential systemic side effects of VEGF block-
ade, some authors advocate pegaptanib over bevacizumab
and ranibizumab in DR, since pegaptanib selectively blocks
VEGF-165, which plays essential role in pathological, but
not physiological neovascularization. This is especially signiﬁ-
cant in patients with DM since they may have co-morbidities
such as increased cardiovascular events, proteinuria and
hypertension.
6.4. VEGF Trap-eye
VEGF has two main receptors, VEGF receptor (VEGFR)-1
and VEGR-2, which bind VEGF-A, VEGF-B, VEGF-C,
and placental growth factor (PGF) (Holash et al., 2002).
VEGF Trap-eye is a recombinant fusion protein consisting
of the VEGF binding domains of VEGFR-1 and VEGFR-2
fused to the Fc domain of human immunoglobulin-G. VEGF
Trap-eye has a higher binding afﬁnity for all VEGF-A iso-
forms, about 140 times greater than ranibizumab (Nguyen
et al., 2006). In addition, VEGF Trap-eye maintains signiﬁcant
intravitreal VEGF-binding activity for 10–12 weeks after a sin-
gle injection (Stewart and Rosenfeld, 2008). The theoretical
advantages of VEGF Trap-eye over ranibizumab include high-
er binding afﬁnity, longer half-life, and ability to inhibit other
molecules such as PGF-1 and PGF-2 which may translate into
clinical beneﬁts of fewer intraocular injections and longer
intervals between injections. Its single intravitreal injection
has been found to be effective in patients with DME (Do
et al., 2009).
7. Combination therapy with intravitreal steroids and anti-
VEGF
To enhance the therapeutic effects of intravitreally adminis-
tered steroids and anti-VEGF drugs, it is logical to administer
both of them together in the vitreous cavity in one sitting.
Hence their intravitreal combination is also being tried in pa-
tients of DR who are refractory to conventional therapy.
Intravitreal combination of TA and bevacizumab seems to
148 A. Pai et al.be effective in improving visual acuity and reducing the macu-
lar thickness in patients with DME who are unresponsive to
laser therapy (Tsilimbaris et al., 2009).8. Combination therapy with laser and intravitreal drugs
Many clinical trials are underway presently to see whether com-
bination of laser with intravitreal drugs helps in any additional
beneﬁts in terms of efﬁcacy and interval of treatments. Theoret-
ically, this combination provides hope of combining the short
term beneﬁt of intravitreal drug (e.g. decreased retinal thickness
and decreased ﬂuid leakage) and the long term beneﬁt of laser
photocoagulation (e.g. reduction in ﬂuid leakage). The
DRCR.net is conducting a phase III multicenter clinical trial
to compare the efﬁcacy of sham intravitreal injection with laser
versus laser combined with 4 mg intravitreal triamcinolone ver-
sus laser combined with 0.5 mg intravitreal ranibizumab versus
0.5 mg intravitreal ranibizumab with deferred laser.9. Enzymatic vitreolysis
The vitreous plays a role in the development of PDR and
DME. The vitreous in diabetic patients undergoes structural
modiﬁcations secondary to enzymatic and non-enzymatic
collagen glycation promoting collagen cross-linking and vitre-
omacular traction; and this can worsen the DME. Further-
more, the retinal new vessels use the posterior hyaloid face
as a scaffold to grow. The retracting vitreous pulls on these
vessels and is responsible for both vitreous hemorrhage and
retinal detachment in PDR. If this vitreous could be detached
early and liqueﬁed, the extent of the complications in PDR can
be reduced. Hence, enzymatic vitreolysis and induction of pos-
terior vitreous detachment is being investigated as a minimally
invasive non-surgical treatment for DR.
Vitreolysis, as a non-surgical treatment in DR, has been
suggested by using many potential enzymes like hyaluronidase
(Kuppermann et al., 2005), plasmin and microplasmin intravit-
really. Hyaluronidase has been found to be non-toxic; and ap-
pears to be effective in the clearance of vitreous hemorrhage
and treatment of DR in Phase III clinical trials (Kuppermann
et al., 2005).10. Conclusions
Diabetic retinopathy, a devastating retinal manifestation of
diabetes mellitus, is a serious global public health problem that
diminishes the quality of life. The number of people worldwide
who are at risk for developing vision loss from diabetes, is pre-
dicted to double over the next 25 years. Since DR can progress
in the absence of symptoms, producing irreversible damage to
the retina, regular screening examinations play a major role in
reducing the magnitude of DR related visual impairment in the
community.
Once DR gets established, the evidence-based therapies
which form the standard of care for DR include strict meta-
bolic control of hyperglycemia, good blood pressure control,
normalization of serum lipids, prompt retinal laser photocoag-
ulation and vitrectomy.
Current techniques of improved laser photocoagulation
and vitrectomy techniques will try in preserving the visual lossfrom DME and PDR. But, some patients may respond poorly
and progressively lose vision in spite of this standard therapy.
Newer insights into the biochemical changes and molecular
events that occur with DM as well as with DR have led to no-
vel treatments which may be effective in patients when the
standard care fails. The therapies which are currently being
used more frequently when the response to the standard care
is un-satisfactory include intravitreal anti-VEGF and cortico-
steroid-based treatment strategies both of which form the sec-
ond-line of therapy. Other new pharmacotherapies on the
horizon also appear exciting at the moment. However, pro-
spective randomized clinical trials are needed to study the role
of all these novel therapies.Disclosure
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